Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nir Sharon

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
CNS Drugs|July 2, 2024
A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical TrialJohn M Kane, Roy Eshet, Eran Harary, et al.
Genetic Testing and Molecular Biomarkers|September 1, 2009
Increased risk for atherosclerosis of various macrophage scavenger receptor 1 allelesRonen Durst, Yehuda Neumark, Vardiella Meiner, et al.
The Lancet. Psychiatry|November 4, 2023
Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and BulgariaJohn M Kane, Eran Harary, Roy Eshet, et al.
Clinical Drug Investigation|February 3, 2026
Safety, Tolerability, and Pharmacokinetics of Subcutaneous Extended-Release Injectable Olanzapine in Patients with Schizophrenia and Schizoaffective DisorderIrina Cherniakov, Avia Merenlender Wagner, Roy Eshet, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
CNS Drugs|July 2, 2024
A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical TrialJohn M Kane, Roy Eshet, Eran Harary, et al.
Genetic Testing and Molecular Biomarkers|September 1, 2009
Increased risk for atherosclerosis of various macrophage scavenger receptor 1 allelesRonen Durst, Yehuda Neumark, Vardiella Meiner, et al.
The Lancet. Psychiatry|November 4, 2023
Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and BulgariaJohn M Kane, Eran Harary, Roy Eshet, et al.
Clinical Drug Investigation|February 3, 2026
Safety, Tolerability, and Pharmacokinetics of Subcutaneous Extended-Release Injectable Olanzapine in Patients with Schizophrenia and Schizoaffective DisorderIrina Cherniakov, Avia Merenlender Wagner, Roy Eshet, et al.
Pageof 3